NASDAQ:PMN ProMIS Neurosciences (PMN) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free PMN Stock Alerts $2.05 -0.01 (-0.49%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$1.99▼$2.1850-Day Range$1.75▼$2.4952-Week Range$0.95▼$8.95Volume3,167 shsAverage Volume39,146 shsMarket Capitalization$38.87 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get ProMIS Neurosciences alerts: Email Address ProMIS Neurosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside290.2% Upside$8.00 Price TargetShort InterestHealthy0.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.11) to ($0.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.90 out of 5 starsMedical Sector384th out of 909 stocksPharmaceutical Preparations Industry171st out of 425 stocks 3.5 Analyst's Opinion Consensus RatingProMIS Neurosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageProMIS Neurosciences has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.17% of the float of ProMIS Neurosciences has been sold short.Short Interest Ratio / Days to CoverProMIS Neurosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProMIS Neurosciences has recently decreased by 0.83%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldProMIS Neurosciences does not currently pay a dividend.Dividend GrowthProMIS Neurosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PMN. Previous Next 3.1 News and Social Media Coverage News SentimentProMIS Neurosciences has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ProMIS Neurosciences this week, compared to 0 articles on an average week.Search Interest9 people have searched for PMN on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows2 people have added ProMIS Neurosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProMIS Neurosciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.30% of the stock of ProMIS Neurosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.13% of the stock of ProMIS Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ProMIS Neurosciences are expected to grow in the coming year, from ($1.11) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProMIS Neurosciences is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProMIS Neurosciences is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProMIS Neurosciences has a P/B Ratio of 10.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About ProMIS Neurosciences Stock (NASDAQ:PMN)ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Read More PMN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMN Stock News HeadlinesApril 17, 2024 | msn.comProMIS Neurosciences (PMN) Price Target Increased by 9.38% to 8.93April 9, 2024 | globenewswire.comProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALSApril 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 4, 2024 | globenewswire.comProMIS Neurosciences to Present in Upcoming Investor Conferences in AprilApril 1, 2024 | globenewswire.comProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent HighlightsMarch 11, 2024 | globenewswire.comProMIS Neurosciences Strengthens Global Intellectual Property PortfolioFebruary 22, 2024 | globenewswire.comProMIS Neurosciences to Present at the 2024 BIO CEO & Investor ConferenceJanuary 22, 2024 | finance.yahoo.comProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein VaccineApril 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. January 3, 2024 | finanznachrichten.deProMIS Neurosciences Inc.: ProMIS Neurosciences, Inc. Announces Leadership TransitionJanuary 3, 2024 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)January 3, 2024 | markets.businessinsider.comProMIS Neurosciences Appoints Neil Warma As Interim Chief Executive OfficerJanuary 3, 2024 | finance.yahoo.comProMIS Neurosciences, Inc. Announces Leadership TransitionNovember 14, 2023 | msn.comProMIS Neurosciences GAAP EPS of -$0.19 beats by $0.14September 6, 2023 | finance.yahoo.comProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 22, 2023 | msn.comProMIS Neurosciences scales 31% on $20.4M private placementAugust 21, 2023 | finance.yahoo.comProMIS Neurosciences Announces $20.4 Million Private Placement FinancingMay 15, 2023 | finance.yahoo.comProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent HighlightsMay 6, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc down on Friday (PMN)April 27, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc up on Thursday (PMN)April 25, 2023 | finance.yahoo.comData Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s DiseaseApril 24, 2023 | finance.yahoo.comProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual MeetingApril 19, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc up on Tuesday (PMN)April 18, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc down on Monday (PMN)April 15, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc up on Friday (PMN)April 10, 2023 | proactiveinvestors.comProMIS Neurosciences submits IND application for Alzheimer's treatmentSee More Headlines Receive PMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/23/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PMN CUSIPN/A CIK1374339 Webwww.promisneurosciences.com Phone(416) 847-6898FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+290.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,210,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-141.23% Debt Debt-to-Equity RatioN/A Current Ratio1.46 Quick Ratio1.46 Sales & Book Value Annual Sales$10,000.00 Price / Sales3,887.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book10.25Miscellaneous Outstanding Shares18,961,000Free Float17,008,000Market Cap$38.87 million OptionableNot Optionable Beta0.67 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Eugene Williams (Age 65)Co-Founder & Chairman Comp: $439.21kMr. Neil K. Warma M.B.A. (Age 61)President, Interim CEO, Principal Executive Officer & Director Comp: $40kDr. Neil R. Cashman M.D. (Age 72)Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director Comp: $333.8kMr. Gavin T. Malenfant (Age 60)Chief Operating Officer Comp: $413.49kMr. Daniel E. Geffken M.B.A. (Age 67)Chief Financial Officer Comp: $90.03kDr. Johanne Kaplan Ph.D. (Age 64)Chief Development Officer Comp: $263.2kDr. Ernest D. Bush Ph.D.Head of Pharmacology/Toxicology & Senior ConsultantDr. David Wishart Ph.D.Chief Physics OfficerMr. Dennis Chen Ph.D.Head of Manufacturing & Senior ConsultantDr. Larry Douglas Altstiel M.D. (Age 74)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsCara TherapeuticsNASDAQ:CARAUnicycive TherapeuticsNASDAQ:UNCYMarker TherapeuticsNASDAQ:MRKRBriaCell TherapeuticsNASDAQ:BCTXEledon PharmaceuticalsNASDAQ:ELDNView All CompetitorsInstitutional OwnershipIeq Capital LLCSold 8,392 shares on 2/7/2024Ownership: 0.163%View All Institutional Transactions PMN Stock Analysis - Frequently Asked Questions Should I buy or sell ProMIS Neurosciences stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ProMIS Neurosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PMN shares. View PMN analyst ratings or view top-rated stocks. What is ProMIS Neurosciences' stock price target for 2024? 2 Wall Street analysts have issued 1-year price objectives for ProMIS Neurosciences' stock. Their PMN share price targets range from $8.00 to $8.00. On average, they expect the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 290.2% from the stock's current price. View analysts price targets for PMN or view top-rated stocks among Wall Street analysts. How have PMN shares performed in 2024? ProMIS Neurosciences' stock was trading at $1.15 on January 1st, 2024. Since then, PMN stock has increased by 78.3% and is now trading at $2.05. View the best growth stocks for 2024 here. When is ProMIS Neurosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PMN earnings forecast. How were ProMIS Neurosciences' earnings last quarter? ProMIS Neurosciences, Inc. (NASDAQ:PMN) posted its quarterly earnings results on Monday, April, 1st. The company reported ($0.09) earnings per share (EPS) for the quarter. How do I buy shares of ProMIS Neurosciences? Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PMN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
